March - 202019the entire procedure is quite expensive and complicated. Our vision is to do the same tests on a cheap disposable cartridge in less than half an hour. It is science fiction, but to have it as an instrument that can be placed in the rural villages of Africa or the most crowded place of the United States, and give extremely reliable diagnostics for thousands of potential pathogens in less than 30 minutes is unfathomable. We think that our innovation is going to revolutionize the way clinical technicians perform present-day diagnostics.Could you elaborate on the futuristic diagnostics platform, "NATlab" that ADOR is set to launch in the market?The NATlab system is the first product that we are going to introduce in the market. It is a compact instrument that will analyze one cartridge at a time, and it is the size of a large shoebox. The system will have a master panel or cockpit, and it will allow users to control one reader or more with a maximum limit of up to 15 units. Each one of these units will report the result of one sample, which will be collected on one disposable cartridge. It is an entirely closed system, which means once we have introduced a sample to the system, nothing can go in or out, or be exposed to external air. Everything is encapsulated within the NATlab system, and by the end of the diagnostic procedure, end-users receive a reading of the results and can prepare to dispose of the waste depending on the test. Every cartridge is suitable for one test sample, such as urine, fecal matter, or blood, as long as it carries DNA that can be collected and introduced to the system. NATlab is designed to directly report the results to the central systems of a hospital or laboratory and is extremely user-friendly. A user can master the system in under an hour. What does the future hold for ADOR over the next 12-18 months?Our diagnostic system is still under development, we have introduced the device at a few medical centers for trials, and the results are extremely promising. ADOR is working with scientists groups from Germany, Israel and the U.S. to develop the system. The reason we scattered our development groups all over the globe is that we carefully chose specialists in every field to contribute to our research, which consists of extremely high precision fluidics, high-level molecular biology and RCA electrochemistry.In terms of operations and market focus, our concentration is in Europe and America. Besides, we plan to introduce our NATlab system at the ECCMID 2020 event at Paris, France in April. Presently, we are building a production facility in Rome that will produce and functionalize cartridges as well as the NATlab system, and the facility is going to be active and fully operational by the end of the year. We plan to finalize our development, complete clinical studies, and launch the product very shortly.
< Page 9 | Page 11 >